Physiological and clinical importance of lipoprotein(a).

L. Romics, I. Karádi, A. Császár, G. M. Kostner

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Lipoprotein(a) is a genetically regulated trait, and its concentration in serum seems to be independent from that of other lipoprotein classes. It can be detected by ultracentrifugation in the d = 1.05-1.12 g/ml density range. Based on epidemiological observations Lp(a) is an independent risk factor for coronary heart disease. Its structure resembles LDL, but contains, in addition to apolipoprotein B 100, the disulphide-linked apoprotein(a). Apoprotein(a) shares a striking homology with plasminogen, consisting multiple repeating domains similar to kringle IV, a single kringle V and an inactive protease segment. The heterogeneity of Lp(a) complex is determined by the apoprotein(a) moiety. It seems so, that atherogenic properties of Lp(a) can be explained by its binding to glycosaminoglycans and inhibition of fibrinolysis. This latter effect is carried out by the kringle domains, which can interact with the plasminogen activators and plasmin binding sites on endothelial surface. The atherogenic properties of Lp(a) are expressed over 30 mg/dL serum concentration. Well-known antilipidemic drugs do not affect its serum level and genetically determined phenotype. Diseases leading to secondary hyperlipoproteinemia may influence the lipoprotein(a) level, too.

Original languageEnglish
Pages (from-to)149-154
Number of pages6
JournalTokai Journal of Experimental and Clinical Medicine
Volume15
Issue number2-3
Publication statusPublished - May 1990

Fingerprint

Kringles
Apoprotein(a)
Lipoprotein(a)
Serum
Apolipoprotein B-100
Hyperlipoproteinemias
Plasminogen Activators
Plasminogen
Fibrinolysin
Ultracentrifugation
Fibrinolysis
Glycosaminoglycans
Disulfides
Lipoproteins
Coronary Disease
Binding Sites
Phenotype
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Physiological and clinical importance of lipoprotein(a). / Romics, L.; Karádi, I.; Császár, A.; Kostner, G. M.

In: Tokai Journal of Experimental and Clinical Medicine, Vol. 15, No. 2-3, 05.1990, p. 149-154.

Research output: Contribution to journalArticle

@article{01dea190104a4088b8300db625727f56,
title = "Physiological and clinical importance of lipoprotein(a).",
abstract = "Lipoprotein(a) is a genetically regulated trait, and its concentration in serum seems to be independent from that of other lipoprotein classes. It can be detected by ultracentrifugation in the d = 1.05-1.12 g/ml density range. Based on epidemiological observations Lp(a) is an independent risk factor for coronary heart disease. Its structure resembles LDL, but contains, in addition to apolipoprotein B 100, the disulphide-linked apoprotein(a). Apoprotein(a) shares a striking homology with plasminogen, consisting multiple repeating domains similar to kringle IV, a single kringle V and an inactive protease segment. The heterogeneity of Lp(a) complex is determined by the apoprotein(a) moiety. It seems so, that atherogenic properties of Lp(a) can be explained by its binding to glycosaminoglycans and inhibition of fibrinolysis. This latter effect is carried out by the kringle domains, which can interact with the plasminogen activators and plasmin binding sites on endothelial surface. The atherogenic properties of Lp(a) are expressed over 30 mg/dL serum concentration. Well-known antilipidemic drugs do not affect its serum level and genetically determined phenotype. Diseases leading to secondary hyperlipoproteinemia may influence the lipoprotein(a) level, too.",
author = "L. Romics and I. Kar{\'a}di and A. Cs{\'a}sz{\'a}r and Kostner, {G. M.}",
year = "1990",
month = "5",
language = "English",
volume = "15",
pages = "149--154",
journal = "Tokai Journal of Experimental and Clinical Medicine",
issn = "0385-0005",
publisher = "Tokai Medical Association",
number = "2-3",

}

TY - JOUR

T1 - Physiological and clinical importance of lipoprotein(a).

AU - Romics, L.

AU - Karádi, I.

AU - Császár, A.

AU - Kostner, G. M.

PY - 1990/5

Y1 - 1990/5

N2 - Lipoprotein(a) is a genetically regulated trait, and its concentration in serum seems to be independent from that of other lipoprotein classes. It can be detected by ultracentrifugation in the d = 1.05-1.12 g/ml density range. Based on epidemiological observations Lp(a) is an independent risk factor for coronary heart disease. Its structure resembles LDL, but contains, in addition to apolipoprotein B 100, the disulphide-linked apoprotein(a). Apoprotein(a) shares a striking homology with plasminogen, consisting multiple repeating domains similar to kringle IV, a single kringle V and an inactive protease segment. The heterogeneity of Lp(a) complex is determined by the apoprotein(a) moiety. It seems so, that atherogenic properties of Lp(a) can be explained by its binding to glycosaminoglycans and inhibition of fibrinolysis. This latter effect is carried out by the kringle domains, which can interact with the plasminogen activators and plasmin binding sites on endothelial surface. The atherogenic properties of Lp(a) are expressed over 30 mg/dL serum concentration. Well-known antilipidemic drugs do not affect its serum level and genetically determined phenotype. Diseases leading to secondary hyperlipoproteinemia may influence the lipoprotein(a) level, too.

AB - Lipoprotein(a) is a genetically regulated trait, and its concentration in serum seems to be independent from that of other lipoprotein classes. It can be detected by ultracentrifugation in the d = 1.05-1.12 g/ml density range. Based on epidemiological observations Lp(a) is an independent risk factor for coronary heart disease. Its structure resembles LDL, but contains, in addition to apolipoprotein B 100, the disulphide-linked apoprotein(a). Apoprotein(a) shares a striking homology with plasminogen, consisting multiple repeating domains similar to kringle IV, a single kringle V and an inactive protease segment. The heterogeneity of Lp(a) complex is determined by the apoprotein(a) moiety. It seems so, that atherogenic properties of Lp(a) can be explained by its binding to glycosaminoglycans and inhibition of fibrinolysis. This latter effect is carried out by the kringle domains, which can interact with the plasminogen activators and plasmin binding sites on endothelial surface. The atherogenic properties of Lp(a) are expressed over 30 mg/dL serum concentration. Well-known antilipidemic drugs do not affect its serum level and genetically determined phenotype. Diseases leading to secondary hyperlipoproteinemia may influence the lipoprotein(a) level, too.

UR - http://www.scopus.com/inward/record.url?scp=0025433374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025433374&partnerID=8YFLogxK

M3 - Article

C2 - 2151833

AN - SCOPUS:0025433374

VL - 15

SP - 149

EP - 154

JO - Tokai Journal of Experimental and Clinical Medicine

JF - Tokai Journal of Experimental and Clinical Medicine

SN - 0385-0005

IS - 2-3

ER -